Loading your page…
Marketing-authorisation holder
3 medicines in 3 countries, as authorisation holder.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
3 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| AEMCOLO194mg base · Tablet, delayed release | Rifamicina | United States | Not marketed | 2018 |
| Lumeblue 25 mg, tablet met verlengde afgifteTablet met verlengde afgifte | Methylthioninechloride x-water | Netherlands | Authorised | 2020 |
| Lumeblue (previously Methylthioninium chloride Cosmo) | Methylthioninium chloride | EU (EMA) | Authorised | 2020 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| European Union (EMA) | 1 | 1 | 0 | CompaniesAll medicines |
| Netherlands | 1 | 1 | 0 | CompaniesAll medicines |
| United States | 1 | 1 | 0 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Report an error or request removalCorrections from the company itself are welcome.
